This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ueda, Y. Articles by Hori, M. Search for Related Content PubMed PubMed Citation Articles by Ueda, Y. Articles by Hori, M. Related Collections Restenosis Animal models of human disease Catheter-based coronary interventions: stents Platelets

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:343-347.)
© 1999 American Heart Association, Inc.

Original Contributions

Glycoprotein IIb/IIIa Antagonist FK633 Could Not Prevent Neointimal Thickening in Stent Implantation Model of Canine Coronary Artery

Yasunori Ueda; Masafumi Kitakaze; Masami Imakita; Hatsue Ishibashi-Ueda; Tetsuo Minamino; Hiroshi Asanuma; Tohru Ozaki; Emiko Imamura; Tsunehiko Kuzuya; Masatsugu Hori

From the Division of Cardiology, The First Department of Medicine, Osaka University School of Medicine, Suita (Y.U., M.K., T.M., H.A., T.K., M.H.); the Department of Pathology, National Cardiovascular Center, Suita (M.I., H.I.-U.); and Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co, Ltd, Osaka, Japan (T.O., E.I.).

Correspondence to Masafumi Kitakaze, MD, Division of Cardiology, The First Department of Medicine, Osaka University School of Medicine, 2-2 Yamadaoka, Suita City, Osaka, 565, Japan.

Abstract—The platelet glycoprotein (GP) IIb/IIIa receptor antagonist appears to reduce the need for revascularization after coronary angioplasty. However, since the effect of GP IIb/IIIa receptor antagonist on the in-stent neointimal thickening has not been clarified, we examined it in the canine model. The beagle dogs were assigned to the control (n=7) or the GP IIb/IIIa receptor antagonist FK633 group (n=7). FK633 was administered by subcutaneous osmotic pumps (0.2 mg · kg^-1 · h^-1) and an intravenous bolus injection (1 mg/kg) before stenting. A coil stent was implanted in the left circumflex coronary arteries. The platelet aggregation capability was significantly (<5%) and consistently reduced by FK633 except for the mild elevation (10% to 30%) on the next day of stenting. Hearts were excised 3 months after stent implantation. The area of intima and media and the area stenosis were obtained from the sections of the stented arteries. The area of intima and media and the area stenosis (1.3±0.2 mm², 41.8±7.5% and 1.3±0.2 mm², 33.9±6.7% in the FK633 and the control group, respectively) were not different between the groups. We conclude that, although GP IIb/IIIa antagonist FK633 prevented the platelet aggregation significantly and consistently, it could not prevent the neointimal thickening after stent implantation in canine coronary artery.

Key Words: restenosis • platelet • glycoprotein IIb/IIIa • stent